CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor being developed for the treatment of dyslipidemia to raise high-density lipoprotein cholesterol. Single doses of CKD-519 up to 400 mg were well tolerated and showed potent inhibition of CETP activity. References: Kim CO, Oh ES, Choi C, Kim Y, Lee S, Kim S, Park MS. Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects. Drug Des Devel Ther. 2016 Nov 15;10:3763-3770. eCollection 2016. PubMed PMID: 27895466; PubMed Central PMCID: PMC5117885.

纯度：≥98%

CAS：1402796-27-3